Physician profile
Dwight S St Clair
NPI 1437175254
$18,463.16
in general payments reported to CMS, 2019-2025
32 companies · $803 in 2025
The $803 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $1,461 · 2021: $1,332 · 2022: $1,551 · 2023: $6,479 · 2024: $5,939 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,660 · Food and Beverage: $3,253 · Travel and Lodging: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,660.00 |
| Food and Beverage | $3,253.01 |
| Travel and Lodging | $307.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $10,518.37 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,014.61 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $948.15 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $660.95 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $560.79 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $527.65 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $527.26 | 2019-2024 | Nuedexta, Rexulti |
| Sunovion Pharmaceuticals INC. | $451.35 | 2019-2022 | |
| Eisai INC. | $412.23 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $368.35 | 2019-2025 | Trintellix |
| Neos Therapeutics, LP | $334.30 | 2019-2024 | Adzenys Xr-Odt |
| Abbvie INC. | $300.00 | 2021-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $264.08 | 2019-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $258.49 | 2019-2025 | Invega Sustenna |
| Ironshore Pharmaceuticals INC. | $237.48 | 2019-2024 | Jornay Pm |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $200.23 | 2022-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $132.91 | 2023-2024 | Quviviq |
| Bausch Health US, LLC | $126.27 | 2021-2022 | |
| Allergan, INC. | $125.24 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $99.85 | 2019-2022 | |
| Corium, LLC | $85.82 | 2022-2023 | Azstarys |
| Adlon Therapeutics L.P. | $67.61 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $44.65 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $40.38 | 2020 | |
| Supernus Pharmaceuticals, INC. | $39.38 | 2023 | Qelbree |
| Almatica Pharma LLC | $37.75 | 2021-2023 | Loreev Xr |
| Alfasigma USA, INC. | $25.04 | 2020 | |
| Noven Therapeutics, LLC | $24.30 | 2023 | Xelstrym |
| Biogen, INC. | $15.10 | 2021 | |
| Shire North American Group INC | $14.57 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight St Clair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.